Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonacog beta pegol in Chinese patients with hemophilia B
CTR20220763Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Started Apr 2022; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20220763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220763.